摘要
断裂检查站和拓扑异构酶II(ToPoII)之间的相互作用是维持基因组完整性至关重要的因素。这种酶的靶向药物已经在癌症治疗的临床应用超过30年,并取得了巨大的成功。已开发的拓扑异构酶II化合物的种类大致分为毒素和催化抑制剂。拓扑异构酶II毒素是一种在临床使用中和常见的化疗药物一样,对正常组织有相当大的毒性抗癌疗法。拓扑异构酶II亚型已经涉及到这种细胞毒性。拓扑异构酶II活性由几种因素决定,其中细胞周期检查点在其敏感性和抑制性方面起着重要的作用。在考虑这些药物的有效性方面,G2/M期检查点尤为重要,本文对此进行了综述。ATM依赖的断裂检查点功能性可能是代表选择癌症治疗的新途径。在这里,我们综述拓扑异构酶II的功能、抗癌机制及目前的催化抑制剂和毒素的局限性以及它们对细胞周期检查点的影响。我们也将探讨这种靶向酶限制正常组织毒性的可能的机制,以及如何由这些药物触发的细胞周期检查点提供一种替代方法和更好的治疗靶点。
关键词: 拓扑异构酶Ⅱ,细胞周期检查点,基因组完整性,细胞毒性,G2/M相检查点,拓扑异构酶Ⅱ毒素
Current Medicinal Chemistry
Title:Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Volume: 24 Issue: 15
关键词: 拓扑异构酶Ⅱ,细胞周期检查点,基因组完整性,细胞毒性,G2/M相检查点,拓扑异构酶Ⅱ毒素
摘要: Interactions between the decatenation checkpoint and Topoisomerase II (TopoII) are vital for maintaining integrity of the genome. Agents that target this enzyme have been in clinical use in cancer therapy for over 30 years with great success. The types of compounds that have been developed to target TopoII are broadly divided into poisons and catalytic inhibitors. The TopoII poisons are in clinical use as anti-cancer therapies, although in common to most chemotherapeutic agents, they display considerable normal tissue toxicity. Inhibition of the TopoIIb isoform has been implicated in this cytotoxicity. Response to TopoII active agents is determined by several factors, but cell cycle checkpoints play a large role in sensitivity and resistance. The G2/M phase checkpoints are of particular importance in considering the effectiveness of these drugs and are reviewed in this article. Functionality of the ATM dependent decatenation checkpoint may represent a new avenue for selective cancer therapy. Here we review the function of TopoII, the anti-cancer mechanisms and limitations of current catalytic inhibitors and poisons, and their influence on cell cycle checkpoints. We will also assess potential new mechanisms for targeting this enzyme to limit normal tissue toxicity, and how the cell cycle checkpoint triggered by these drugs may provide an alternative and possibly better target for novel therapies.
Export Options
About this article
Cite this article as:
Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints, Current Medicinal Chemistry 2017; 24 (15) . https://dx.doi.org/10.2174/0929867323666161205122613
DOI https://dx.doi.org/10.2174/0929867323666161205122613 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry MDR Reversal by Deprenylated Tetracyclic and Hexacyclic Analogues of N-Acetylardeemin: Confirmation of the Ardeemin Pharmacophore
Letters in Drug Design & Discovery The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Current Stem Cell Research & Therapy Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy